Company profile
Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Dichlorphenamide | approved | — | 0 | — |
| Glucagon | approved | — | 7 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02937558 | phase2 | completed | 2016-10-01 | 2018-09-01 | Xeris Pharmaceuticals | CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism |
| NCT02733588 | phase2 | completed | 2016-03-01 | 2017-04-05 | Xeris Pharmaceuticals | Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients |
| NCT03738865 | phase3 | completed | 2018-09-27 | 2019-03-29 | Xeris Pharmaceuticals | G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes |
| NCT03439072 | phase3 | completed | 2018-01-23 | 2018-04-18 | Xeris Pharmaceuticals | G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes |
| NCT02423980 | phase2 | completed | 2015-04-01 | 2015-05-01 | Xeris Pharmaceuticals | G-Pen™ for Hypoglycemia Rescue in T1D Patients |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 011366 | NDA | XERIS PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 212097 | NDA | XERIS PHARMACEUTICALS INC | ||||
Loading… | ||||||